A Research Study Looking at Specific Tissue of the Umbilical Cord
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01166776|
Recruitment Status : Completed
First Posted : July 21, 2010
Last Update Posted : August 22, 2016
|Condition or disease|
|Varices of Umbilical Cord|
|Study Type :||Observational|
|Actual Enrollment :||64 participants|
|Official Title:||Decellularization of Umbilical Cord Wharton's Jelly for Tissue Regenerative Applications Including Avascular Necrosis|
|Study Start Date :||June 2010|
|Actual Primary Completion Date :||April 2016|
|Actual Study Completion Date :||July 2016|
To isolate Umbilical cord Wharton's jelly matrix to be used as a scaffold for tissue regenerative applications, including avascular necrosis.
- Isolation and decellularization of umbilical cord Wharton's jelly matrix [ Time Frame: Immediately upon delivery ]Use the Wharton's Jelly matrix as a scaffold, we should be able to remove the cellular components of Wharton's Jelly. This decellularization process will help decrease antigenicity and accordingly avoid allosensitization. Additionally, the matrix should be able to provide a 3 dimensional (3D) environment needed for biologic and geometric recellularization.
- Study the ability of the isolated and decellularized matrix to support recellularization with mesenchymal stem cells and to support their growth and differentiation [ Time Frame: Within 24 hours ]Use the decellularized matrix for tissue regeneration purposes, it should be able to support recellularization with undifferentiated mesenchymal stem cells and help support their differentiation into different tissues, including bone or cartilage.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01166776
|United States, Kansas|
|University of Kansas Medical Center|
|Kansas City, Kansas, United States, 66160|
|United States, Missouri|
|Children's Mercy Hospital|
|Kansas City, Missouri, United States, 64108|
|Principal Investigator:||Omar Aljitawi, MD||University of Kansas Medical Center|